StockNews.AI
ARVN
StockNews.AI
74 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN

1. Pomerantz LLP is investigating potential securities fraud by Arvinas executives. 2. Arvinas canceled two Phase 3 trials with Pfizer, affecting its pipeline. 3. The company announced a workforce reduction of one-third to streamline operations. 4. On May 1, stock price fell 24.84% to $7.23 following these announcements.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Arvinas faces serious allegations and major operational setbacks, historically leading to price declines.

How important is it?

The investigation and trial cancelations point to company instability, highly relevant to ARVN investors.

Why Short Term?

Immediate negative sentiment due to fraud investigation and reduced workforce; expected to impact stock quickly.

Related Companies

PFE
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. (“Arvinas” or the “Company”) (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 1, 2025, Arvinas issued a press release announcing that the Company and its development partners at Pfizer had “removed plans for a Phase 3 first-line combination trial with atirmociclib, as well as the planned Phase 3 second-line combination trial with a CDK4/6 inhibitor, from our joint development plan.”  Arvinas’s Chief Executive Officer said that the “decision was made following a review of the totality of emerging information, including external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation.”  Arvinas also “[a]nnounced a reduction in workforce of approximately one-third across the Company to streamline operations across the organization and enable the efficient progression of the Company’s portfolio”, advising that “[t]he reduction is planned to be completed in the second quarter of 2025.”  On this news, Arvina’s stock price fell $2.39 per share, or 24.84%, to close at $7.23 per share on May 1, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News